EGIS 3966

Drug Profile

EGIS 3966

Latest Information Update: 31 Mar 1995

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Japan Tobacco
  • Class Antiarrhythmics
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
  • 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in Philippines (Unknown route)
  • 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in South Korea (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top